Orna Therapeutics Raises $251M Series B

Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases

Key Highlights

• Funding Amount: $251M Series B
• Valuation: Undisclosed
• Headquarters: Cambridge, MA
• Founded: 2019
• Employees: 100-200
• Total Raised: $313M

About the Funding Round

Orna Therapeutics has successfully closed $251M Series B in funding, marking a significant milestone in the company's growth trajectory. This investment will enable the company to accelerate product development, expand market reach, and strengthen its position in the biotech sector.

Investor Syndicate

The round was backed by a prestigious group of investors:

• Flagship Pioneering
• Invus
• Mubadala

This diverse group of investors brings not only capital but also strategic expertise and valuable networks that will help Orna Therapeutics achieve its ambitious goals.

Market Opportunity

The biotech market continues to experience rapid growth, driven by increasing demand for innovative solutions and digital transformation across industries. Orna Therapeutics's unique approach and proven technology position it well to capture significant market share in the coming years.

Company Background

Founded in 2019 and headquartered in Cambridge, MA, Orna Therapeutics has established itself as an innovative player in the biotech space. With 100-200 employees, the company has built a strong team focused on delivering exceptional value to customers.

Next Steps

With this new funding, Orna Therapeutics plans to:

• Accelerate product development and innovation
• Expand into new markets and geographies
• Grow the team across engineering, sales, and operations
• Strengthen partnerships with key industry players
• Scale infrastructure to support rapid growth

Industry Impact

This funding round represents a strong vote of confidence in Orna Therapeutics's vision and execution. The investment will help drive innovation in the biotech sector and create new opportunities for customers and partners.

For more information about Orna Therapeutics, visit their website or contact their press office.